Traffic
459.45K
+13.57%MoMEstimated monthly visits
496.21K330.81K165.4K0
Global rank
136,240
Country rank · United States
28,409
Category rank · Pharmacy
56
Average visit duration
00:34
Pages per visit
1.37
Bounce rate
73.27%
Domain age
27 years
Search share
2.5%
Traffic sources
- Display ads72.8%
- Paid search10.9%
- Direct9.4%
- Social3.4%
- Search2.5%
- Other0.6%
- Referrals0.2%
- Email0.1%
- Generative AI0.0%
Regions
- United States85.1%
- Vietnam2.3%
- Canada2.2%
- United Kingdom2.0%
- Australia1.5%
See how xolair.com compares with the most visited websites in the world, the fastest growing websites and sites gaining organic search traffic.
Search visibility
Keyword samples
Estimated visitsMonthly searchesVisits ÷ searches
- xolairBRAND1.51K14.01K11%
- omalizumabBRAND47014.95K3%
- xolair injectionBRAND4701.74K27%
- zolare32098033%
- xolair food allergyBRAND32038084%
Keyword rankings
Keyword rankings
86.4M
Search estimate
New 1 · Up 2
- Ranking keywords
- 12,400
- Landing pages
- 4
- Search competitors
- 4
- AI citations
- 2
PositionEstimated visits
- google#142M
- gmail#118.2M
- google maps#19.4M
- google drive#14.1M
Full keyword rankings are a Pro feature
Unlock ProSite profile
- HTTP 200
- Email authentication
- Hosting ASN
- HTTP
- 200
- Page size
- 154.9 KiB
- Hosting
- AMAZON-02 · AS16509
- Email authentication
- DMARC reject
- TLS
- TLSv1.3 · 136 days
Page and SEOSchema 5
- Final URL
- https://www.xolair.com/
- Title
- XOLAIR® (omalizumab) | Allergic Asthma, CSU, CRSwNP & Food Allergy Treatment
- Description
- Learn about XOLAIR®, a self-administered treatment for allergic asthma, chronic rhinosinusitis with nasal polyps, chronic spontaneous urticaria, and food allergy. See full prescribing, safety, & Boxed Warning info.
- Cross-origin redirect
- Yes
- Word count
- 1,889
- Internal / external links
- 9 / 5
- Canonical
- https://www.xolair.com/
- Language
- en-US
- H1 / H2
- 1 / 1
- Images missing alt
- 11 / 12
- Schema
- ContactPoint · Drug · MedicalWebPage · Organization · PostalAddress
- OG / Twitter
- OG · Twitter
- OG locale
- en_US
Technology and tracking4 technologies
- Technology clues
- Bootstrap · jQuery · React · Bot protection
- External script hosts
- nexus.ensighten.com · google.com
- Server
- Apache
- Security headers
- 3 / 6
- HSTS / CSP
- HSTS
Email and DNS securitySet
- SPF
- Not found
- DMARC
- Set · reject
- DKIM selectors
- Not found
- IPv6
- No AAAA
- Site verification TXT
- SOA
- dns1.novartis.com
- NS
- a7-64.akam.net. · a28-67.akam.net. · a2-66.akam.net. · 7 more
Hosting and networkAS16509
- A
- 54.193.66.173
- Hosting ASN
- AS16509 · 54.193.0.0/17
- Hosting organization
- AMAZON-02 - Amazon.com, Inc.
- Hosting country
- US
- BGP announcement
- Yes
- Reverse DNS
- ec2-54-193-66-173.us-west-1.compute.amazonaws.com
- TLS
- TLSv1.3 · Verified
- Certificate issuer
- Amazon RSA 2048 M04
- Certificate remaining
- 136 days
- Certificate SAN
- DNS:www.xolair.com · DNS:xolair.com
robots and AI crawlingHTTP 200
- Robots.txt
- 200
- Global Disallow /
- No
- Sitemap
- URL set · 84
- AI explicitly disallowed
- 0
- AI explicitly allowed
- 16
Well-known public paths
- Present / checked
- 0 / 5
Website information
- Domain
- xolair.com
- Registration status
- Domain registered
- Registered
- 1999-12-08
- Registrar
- MarkMonitor Inc.
- Expires
- 2027-12-08
- Domain age
- 27 years
- DNSSEC
- No
- Registry status
- client delete prohibited · client transfer prohibited · client update prohibited
Similar sites
Website reports in the same category, with nearby monthly visits.
- pharmazone.com
- dulcolax.com
- webapoteket.dk
- extrafarma.com.br
- farmaciasespecializadas.com
- drogariastamoio.com.br
- pharm24.gr
- skyrizi.com
What's in this report
The report starts with a whole-site monthly visit estimate. Search visibility and public site facts follow when they exist.
- Website traffic is a modeled whole-site estimate, with a source, observation period and confidence.
- Search visibility is ranking keywords and search traffic, listed separately from whole-site visits.
- Missing or partial values stay marked in the report.